Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
News Sep 29, 2008
Oramed Pharmaceuticals, Inc. has announced that it has commenced Phase 2A studies of ORMD 0801, its oral insulin capsule, on Type 1 diabetics at the Hadassah University Medical Center in Jerusalem, Israel.
Oramed’s Phase 2A trial is focused on assessing the safety and efficacy of its oral insulin capsule on nine Type 1 diabetes patients.
The start of this clinical trial on Type 1 Diabetic patients follows completion by the company of similar trials on Type 2 diabetic patients, which demonstrated that ORMD 0801 had a good safety profile and was effective in lowering blood glucose levels without any serious adverse events.
“The commencement of trials of our oral insulin capsule on Type 1 diabetics signals another major step forward for our company in the treatment of diabetes,” said Nadav Kidron, Oramed CEO. “The successful results from our trials on Type 2 diabetics were very encouraging and we hope to achieve similar results from our Type 1 trials as well.”
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018